Spectrum Pharmaceuticals, Inc. SPPIannounced encouraging data from preliminary analysis of a phase II study evaluating its pan-HER inhibitor, poziotinib, in EGFR Exon 20 Mutant non-small cell lung cancer (“NSCLC”). The study is being conducted by MD Anderson Cancer Center of the University of Texas.
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться